Related Experiment Video
Updated: Jun 4, 2026

The Lambda Select cII Mutation Detection System
Published on: April 26, 2018
Genotoxicity and carcinogenicity studies of antihistamines
Giovanni Brambilla1, Francesca Mattioli, Luigi Robbiano
1Department of Internal Medicine, Division of Clinical Pharmacology and Toxicology, University of Genoa, Viale Benedetto XV 2, 16132 Genoa, Italy.
Abstract:
This review provides a compendium of the results of genotoxicity and carcinogenicity assays performed on marketed antihistamines. Of the 70 drugs examined, 29 (41.4%) have at least one genotoxicity and/or carcinogenicity test result: 12 tested positive in at least one genotoxicity assay, six in at least one carcinogenicity assay, and four gave a positive response in both at least one genotoxicity assay and at least one carcinogenicity assay. Of 19 drugs with both genotoxicity and carcinogenicity data, eight were neither genotoxic nor carcinogenic, two were carcinogenic in at least one sex of mice or rats but tested negative in genotoxicity assays, five tested positive in at least one genotoxicity assay but were non-carcinogenic, and four gave a positive response in at least one genotoxicity assay and in at least one carcinogenicity assay. Only 12 (17.1%) of the 70 drugs examined have all data required by present guidelines for testing of pharmaceuticals, but it should be considered that a large fraction of them were developed and marketed prior the present regulatory climate.
Insights
Many marketed antihistamines lack complete genotoxicity and carcinogenicity data. A significant portion of tested drugs showed positive results in these safety assays, highlighting potential risks.
Area of Science:
- Pharmacology
- Toxicology
- Drug Safety Evaluation
Background:
- Antihistamines are widely used medications for allergic conditions.
- Comprehensive safety data, including genotoxicity and carcinogenicity, is crucial for marketed drugs.
- Regulatory requirements for drug safety testing have evolved over time.
Purpose of the Study:
- To review and compile genotoxicity and carcinogenicity assay results for marketed antihistamines.
- To assess the completeness of safety data for these drugs based on current guidelines.
- To identify antihistamines with positive findings in safety assays.
Main Methods:
- Systematic review of published literature and regulatory documents.
- Compilation of genotoxicity assay data (e.g., Ames test, chromosomal aberration assays).
- Compilation of carcinogenicity assay data from rodent studies.
Main Results:
- Out of 70 examined antihistamines, 29 (41.4%) had available genotoxicity and/or carcinogenicity data.
- 12 drugs tested positive in genotoxicity assays, six in carcinogenicity assays, and four in both.
- Only 12 (17.1%) of the drugs met all current data requirements, with many developed before stringent regulations.
Conclusions:
- A substantial number of marketed antihistamines lack comprehensive genotoxicity and carcinogenicity data.
- Positive findings in safety assays were observed for several drugs, warranting further investigation.
- The review underscores the need for updated safety assessments, especially for older medications.
More Related Videos
04:12Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)
Published on: December 19, 2019
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
Related Concept Videos
Mutagenicity and Carcinogenicity
Drug Toxicity: Dose-Dependent Reactions
Physical Properties of Amines
Toxicity Testing in Animals
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Drug Toxicity: Allergic Reactions